Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
Molina, Jean-Michel, Dr, Prof, Cahn, Pedro, MD, Grinsztejn, Beatriz, MD, Lazzarin, Adriano, Prof, Mills, Anthony, MD, Saag, Michael, Prof, Supparatpinyo, Khuanchai, Prof, Walmsley, Sharon, Prof, Crauwels, Herta, PhD, Rimsky, Laurence T, PhD, Vanveggel, Simon, MSc, Boven, Katia, MD
Published in The Lancet (British edition) (16.07.2011)
Published in The Lancet (British edition) (16.07.2011)
Get full text
Journal Article
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
Sax, Paul E, Dr, DeJesus, Edwin, MD, Mills, Anthony, MD, Zolopa, Andrew, Prof, Cohen, Calvin, MD, Wohl, David, MD, Gallant, Joel E, Prof, Liu, Hui C, PhD, Zhong, Lijie, PhD, Yale, Kitty, BA, White, Kirsten, PhD, Kearney, Brian P, Pharm D, Szwarcberg, Javier, MD, Quirk, Erin, MD, Cheng, Andrew K, MD
Published in The Lancet (British edition) (30.06.2012)
Published in The Lancet (British edition) (30.06.2012)
Get full text
Journal Article
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study
Mills, Anthony, MD, Arribas, Jose R, MD, Andrade-Villanueva, Jaime, Prof, DiPerri, Giovanni, MD, Van Lunzen, Jan, Prof, Koenig, Ellen, MD, Elion, Richard, MD, Cavassini, Matthias, MD, Madruga, Jose Valdez, MD, Brunetta, Jason, MD, Shamblaw, David, MD, DeJesus, Edwin, MD, Orkin, Chloe, MBBch, Wohl, David A, MD, Brar, Indira, MD, Stephens, Jeffrey L, MD, Girard, Pierre-Marie, Prof, Huhn, Gregory, MD, Plummer, Andrew, BS, Liu, Ya-Pei, PhD, Cheng, Andrew K, MD, McCallister, Scott, Dr
Published in The Lancet infectious diseases (01.01.2016)
Published in The Lancet infectious diseases (01.01.2016)
Get full text
Journal Article
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial
Pozniak, Anton, Dr, Markowitz, Martin, Prof, Mills, Anthony, MD, Stellbrink, Hans-Juergen, MD, Antela, Antonio, MD, Domingo, Pere, Prof, Girard, Pierre-Marie, MD, Henry, Keith, Prof, Nguyen, Thai, MD, Piontkowsky, David, MD, Garner, Will, PhD, White, Kirsten, PhD, Guyer, Bill, PharmD
Published in The Lancet infectious diseases (01.07.2014)
Published in The Lancet infectious diseases (01.07.2014)
Get full text
Journal Article
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Madruga, José Valdez, Dr, Cahn, Pedro, MD, Grinsztejn, Beatriz, MD, Haubrich, Richard, Prof, Lalezari, Jacob, MD, Mills, Anthony, MD, Pialoux, Gilles, Prof, Wilkin, Timothy, MD, Peeters, Monika, MSc, Vingerhoets, Johan, PhD, de Smedt, Goedele, MD, Leopold, Lorant, MD, Trefiglio, Roberta, PharmD, Woodfall, Brian, MD
Published in The Lancet (British edition) (07.07.2007)
Published in The Lancet (British edition) (07.07.2007)
Get full text
Journal Article
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Sax, Paul E, DeJesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Dretler, Robin, Mills, Anthony, Brinson, Cynthia, Peloquin, Julie, Wei, Xuelian, White, Kirsten, Cheng, Andrew, Martin, Hal, Quirk, Erin
Published in The lancet HIV (01.04.2017)
Published in The lancet HIV (01.04.2017)
Get more information
Journal Article
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
Orkin, Chloe, DeJesus, Edwin, Ramgopal, Moti, Crofoot, Gordon, Ruane, Peter, LaMarca, Anthony, Mills, Anthony, Vandercam, Bernard, de Wet, Joseph, Rockstroh, Jürgen, Lazzarin, Adriano, Rijnders, Bart, Podzamczer, Daniel, Thalme, Anders, Stoeckle, Marcel, Porter, Danielle, Liu, Hui C, Cheng, Andrew, Quirk, Erin, SenGupta, Devi, Cao, Huyen
Published in The lancet HIV (01.05.2017)
Published in The lancet HIV (01.05.2017)
Get more information
Journal Article
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
DeJesus, Edwin, Ramgopal, Moti, Crofoot, Gordon, Ruane, Peter, LaMarca, Anthony, Mills, Anthony, Martorell, Claudia T, de Wet, Joseph, Stellbrink, Hans-Jürgen, Molina, Jean-Michel, Post, Frank A, Valero, Ignacio Pérez, Porter, Danielle, Liu, YaPei, Cheng, Andrew, Quirk, Erin, SenGupta, Devi, Cao, Huyen
Published in The lancet HIV (01.05.2017)
Published in The lancet HIV (01.05.2017)
Get more information
Journal Article